PBM Stock Overview
Engages in the development of botanical psilocybin-based psychedelic medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Psyence Biomedical Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.054 |
| 52 Week High | US$14.55 |
| 52 Week Low | US$0.048 |
| Beta | -0.42 |
| 11 Month Change | -50.09% |
| 3 Month Change | -89.69% |
| 1 Year Change | -99.53% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| PBM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -28.8% | -10.5% | -2.1% |
| 1Y | -99.5% | 12.7% | 29.7% |
Return vs Industry: PBM underperformed the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: PBM underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| PBM volatility | |
|---|---|
| PBM Average Weekly Movement | 20.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PBM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PBM's weekly volatility has decreased from 27% to 20% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Neil Maresky | www.psyencebiomed.com |
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
Psyence Biomedical Ltd. Fundamentals Summary
| PBM fundamental statistics | |
|---|---|
| Market cap | US$844.85k |
| Earnings (TTM) | -US$51.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs PBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$51.16m |
| Earnings | -US$51.16m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -95.2% |
How did PBM perform over the long term?
See historical performance and comparison